Blood Thinners Significantly Reduce Heart Failure Sequel Risk
By HospiMedica International staff writers Posted on 13 May 2019 |
Image: A new study claims blood thinners can reduce potential cardiovascular dangers in HF patients (Photo courtesy of Fotolia).
Using blood thinners in patients with congestive heart failure (CHF), coronary artery disease (CAD), or irregular heart rhythms can reduce the risk of subsequent thromboembolic events, claims a new study.
Researchers at the University of California, San Diego (UCSD, USA), Université de Lorraine (Nancy, France), and other institutions conducted a mulicenter, placebo-controlled study that randomized 5,022 patients who were discharged from a hospital or an outpatient clinic after treatment for worsening CHF between September 2013 and October 2017. The patients were randomly assigned to receive either 2.5 mg of rivaroxaban (Xarelto) given orally twice daily or placebo, in addition to their standard therapy.
The main outcomes and measures were a thromboembolic composite of myocardial infarction, ischemic stroke, sudden/unwitnessed death, symptomatic pulmonary embolism or symptomatic deep venous thrombosis (DVT), or all of the components except sudden/unwitnessed deaths, since not all of these are caused by thromboembolic events. The results showed Rivaroxaban was associated with 2.4% reduced risk of thromboembolic events when compared to the placebo (from 15.5% to 13.1%) when sudden/unwitnessed deaths were included, and from 7.6% to 6.1% without. The study was published in the April 2019 issue of JAMA Cardiology.
“We initially wanted to know if we could improve outcomes in patients after an episode of worsening heart failure using a low dose of blood thinner. While this strategy didn't accomplish that goal, it was associated with a significant reduction in the risk of clinically important events caused by thrombosis – stroke, heart attack and sudden cardiac death,” said lead author Professor Barry Greenberg, MD, of UCSD. “Although there was some increase in bleeding risk with low-dose rivaroxaban, major bleeding, which was the primary safety endpoint of the study, was not significantly increased.”
Rivaroxaban, a novel oral anticoagulant (NOAC), is a highly selective Factor Xa inhibitor that acts against both free Factor Xa and Factor Xa bound in the prothrombinase complex. It does not inhibit thrombin and no effects on platelets have been demonstrated. As such, it allows predictable anticoagulation, but does not require frequent laboratory monitoring, dosing adjustments, or dietary restrictions, and incurs fewer drug interactions than warfarin. On the other hand, it does not have specific reversal agents, and may require dosage adjustment based on patient renal function.
Related Links:
University of California, San Diego
Université de Lorraine
Researchers at the University of California, San Diego (UCSD, USA), Université de Lorraine (Nancy, France), and other institutions conducted a mulicenter, placebo-controlled study that randomized 5,022 patients who were discharged from a hospital or an outpatient clinic after treatment for worsening CHF between September 2013 and October 2017. The patients were randomly assigned to receive either 2.5 mg of rivaroxaban (Xarelto) given orally twice daily or placebo, in addition to their standard therapy.
The main outcomes and measures were a thromboembolic composite of myocardial infarction, ischemic stroke, sudden/unwitnessed death, symptomatic pulmonary embolism or symptomatic deep venous thrombosis (DVT), or all of the components except sudden/unwitnessed deaths, since not all of these are caused by thromboembolic events. The results showed Rivaroxaban was associated with 2.4% reduced risk of thromboembolic events when compared to the placebo (from 15.5% to 13.1%) when sudden/unwitnessed deaths were included, and from 7.6% to 6.1% without. The study was published in the April 2019 issue of JAMA Cardiology.
“We initially wanted to know if we could improve outcomes in patients after an episode of worsening heart failure using a low dose of blood thinner. While this strategy didn't accomplish that goal, it was associated with a significant reduction in the risk of clinically important events caused by thrombosis – stroke, heart attack and sudden cardiac death,” said lead author Professor Barry Greenberg, MD, of UCSD. “Although there was some increase in bleeding risk with low-dose rivaroxaban, major bleeding, which was the primary safety endpoint of the study, was not significantly increased.”
Rivaroxaban, a novel oral anticoagulant (NOAC), is a highly selective Factor Xa inhibitor that acts against both free Factor Xa and Factor Xa bound in the prothrombinase complex. It does not inhibit thrombin and no effects on platelets have been demonstrated. As such, it allows predictable anticoagulation, but does not require frequent laboratory monitoring, dosing adjustments, or dietary restrictions, and incurs fewer drug interactions than warfarin. On the other hand, it does not have specific reversal agents, and may require dosage adjustment based on patient renal function.
Related Links:
University of California, San Diego
Université de Lorraine
Latest Critical Care News
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration